Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary disease characterized by progressive atrophy of skeletal muscles, primarily the muscles of the shoulder girdle, shoulder blades and face. This disease belongs to the group of myodystrophies and has a specific phenotype, which manifests itself in the form of asymmetric weakness and muscle atrophy, which leads to functional impairment and a significant decrease in the quality of life of patients. The use of modern molecular genetics methods allows not only to establish a diagnosis, but also to identify a predisposition to the disease and the progression of symptoms, which is especially important for effective prevention and treatment.
History of the disease and interesting historical facts
Facioscapulohumeral muscular dystrophy was first described in 1891 by the French physician Jean-Louis Benjamin. Since then, the disease has been the subject of much research, and its genetic aspects were only established at the end of the 20th century. One of the first examples of familial transmission of FSHD was reported in several European countries, indicating the genetic nature of the disorder. Interestingly, the influence of social and cultural factors on the course of the disease indicates the importance of early diagnosis and the involvement of a multidisciplinary team of specialists in the treatment and support of patients.
Epidemiology
Facioscapulohumeral muscular dystrophy has a relatively low prevalence, with estimates ranging from 1 to 10 cases per 100,000 population depending on the region. The disease is more common in males and has a chromosomal inheritance pattern, indicating its polygenetic nature. Given that the disease is associated with genetic mutations, there is a need for a more in-depth study of the genetic basis of this disorder in different ethnic groups.
Genetic predisposition to this disease
FSHD is caused by mutations in a number of genes, the most commonly mentioned of which are the dystrophin and phospholambant genes. These mutations lead to disruption of protein synthesis, which ultimately causes muscle tissue degeneration. Research shows that some mutations promote more pronounced clinical symptoms and progression, which requires an individualized approach to treatment. Genetic analysis for mutations helps in implementing appropriate treatment measures and predicting the course of the disease.
Risk factors for the development of this disease
Risk factors for FSHD include:
- Heredity: A family history significantly increases the risk of developing the disease.
- Genetic mutations: Specific mutations in a body of genes lead to increased severity of the disease.
- Environmental factors: Certain chemicals may be associated with mutations, which requires further study.
- Patient's physical status: level of physical activity and previous illnesses can influence the course of the disease.
Diagnosis of this disease
The diagnosis of FSHD is based on the following methods:
- General symptoms: the onset of the disease usually occurs in childhood or adolescence, with characteristic weakness and atrophy of the muscles of the shoulder girdle and face.
- Laboratory tests: Diagnosis is confirmed by testing blood for creatine phosphokinase (CPK) levels, which are often elevated.
- Radiological examinations: magnetic resonance imaging allows us to assess the degree of muscle atrophy and identify their pathologies.
- Other diagnostic tests: Electromyography may be used to assess the electrical activity of the affected muscles.
- Differential diagnosis: it is necessary to exclude other types of myopathies and neurodegenerative diseases that may have similar clinical manifestations.
Treatment
Treatment of FSHD is multifaceted and includes:
- General treatment: supportive therapy aimed at maintaining muscle function.
- Pharmacological treatment: use of steroids, muscle relaxants and other medications to improve muscle function.
- Surgical treatment: surgical interventions may be used in cases of significant deformation and dysfunction.
- Other treatments include physical therapy and rehabilitation programs that aim to improve patients' quality of life and maintain optimal physical activity.
List of medications used to treat this disease
The consolidated list of drugs includes:
- Dexafetazone
- Prednisolone
- Tizanidin
- memantine
Disease monitoring
Monitoring of the patient's condition includes:
- Control stages: regular examinations by a neurologist, as well as genetic counseling to assess the progression of the disease.
- Prognosis: The prognosis depends on the degree of muscle damage and the individual characteristics of the course of the disease.
- Complications: respiratory disorders and cardiovascular diseases are possible in the later stages of the disease.
Age-related features of the disease
Age-related features are manifested as follows:
- Childhood and adolescence: Primary symptoms usually occur between the ages of 5 and 15 years.
- Adulthood: the course of the disease in adulthood is often less severe, but the risk of complications remains.
- Old age: Most patients experience significant deterioration in their condition and possible comorbidities in old age.
Questions and Answers
- What is LFPD? FSHD is a hereditary disease characterized by progressive atrophy of the skeletal muscles of the shoulder girdle and face.
- What is the cause of FSHD? FSHD is caused by mutations in certain genes that are responsible for the synthesis of proteins necessary for normal muscle function.
- How to diagnose the disease? Diagnosis includes clinical examination, laboratory tests, magnetic resonance imaging and electromyography.
- How to treat FSHD? Treatment involves a combination of supportive care, pharmacological treatment and, in some cases, surgery.
- What is the prognosis for patients with FSHD? The prognosis depends on the individual characteristics of the disease, but patients may experience a decrease in quality of life due to progressive symptoms.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends regular medical check-ups and early diagnostics to reduce the risk of complications. It is important to maintain a physical activity regimen adapted to the individual capabilities of the patient, helping to maintain muscle strength and overall health. Maintaining a psychological state also plays a significant role in treatment, so it is recommended to seek support from specialists in psychology and social adaptation.
